FDA approves Genentech’s Xolair for food allergies: A new horizon in allergy treatment
The U.S. Food and Drug Administration (FDA) has approved Xolair (omalizumab) for reducing allergic reactions, including anaphylaxis, that may occur with accidental exposure to foods ... Read More
Genentech’s Phase 3 study of inavolisib in breast cancer reveals positive results
Genentech, part of the Roche Group, has presented compelling results from the Phase III INAVO120 study, evaluating the effectiveness of inavolisib in combination with palbociclib ... Read More
Roche’s Vabysmo gains FDA approval for treating retinal vein occlusion
Pharma giant Roche has secured the U.S. FDA's approval for Vabysmo (faricimab) in treating macular edema after retinal vein occlusion (RVO). This becomes the third ... Read More
Roche announces $7.1bn deal to acquire Telavant and RVT-3101 antibody
Switzerland-based Roche has officially declared its acquisition agreement for Telavant Holdings, Inc., a Roivant company collaboratively owned by Roivant Sciences Ltd. and Pfizer Inc. The ... Read More
Roche, Alnylam’s Zilebesiran meets primary endpoint in KARDIA-1 trial
Breaking news in the world of hypertension treatment, Roche and Alnylam Pharmaceuticals have announced the success of their Phase 2 study KARDIA-1. The investigational RNAi ... Read More
Genentech’s Alecensa shows promise in Phase III ALINA study for early-stage ALK-positive NSCLC
Genentech, a Roche Group member, has announced positive results from its Phase III ALINA study evaluating Alecensa (alectinib), setting a new standard for treating early-stage ... Read More
Genentech gets Actemra FDA approval for COVID-19 in hospitalized adults
Actemra FDA approval : Genentech, a subsidiary of Roche, has received the approval of the US Food and Drug Administration (FDA) for Actemra (tocilizumab) intravenous ... Read More